Latest Period
Q4 2025
Security Snapshot
Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN) Institutional Ownership
CUSIP: 30054Y107
13F Institutional Holders and Ownership History from Q4 2025 to Q1 2026
Institutions Reporting
59
Shares (Excl. Options)
27,200,904
Price
$17.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- EVMN on NYSE
- Shares outstanding
- 35,974,918
- Price per share
- $27.01
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 27,200,904
- Total reported value
- $465,685,578
- % of total 13F portfolios
- 0.01%
- Share change
- +23,579,060
- Value change
- +$403,679,610
- Number of holders
- 59
- Price from insider filings
- $27.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- EVMN - Evommune, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 30054Y107.
- 59 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 59 to 18 between Q4 2025 and Q1 2026.
- Reported value moved from $465,685,578 to $31,056,144.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 59 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 30054Y107?
CUSIP 30054Y107 identifies EVMN - Evommune, Inc. - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 30054Y107:
Significant Owners of Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 15% | -6.2% | $114,491,976 | +$7,765,422 | 5,288,313 | +7.3% | LSP 7 Cooperatieve U.A. | 12 Feb 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | -12% | $70,347,063 | +$722,023 | 3,494,638 | +1% | RA Capital Management, L.P. | 12 Feb 2026 |
| Pivotal bioVenture Partners Fund I, L.P. | 11% | $69,158,608 | 3,435,599 | Nan Fung Group Holdings Limited | 31 Dec 2025 | |||
| Andera Partners | 6% | 1,897,362 | Andera Partners | 07 Nov 2025 |
As of 31 Dec 2025, 59 institutional investors reported holding 27,200,904 shares of Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN). This represents 76% of the company’s total 35,974,918 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN) together control 71% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 14% | 4,929,633 | 7.6% | $84,395,317 | |
| RA CAPITAL MANAGEMENT, L.P. | 9.6% | 3,458,770 | 0.61% | $59,214,142 | |
| Pivotal bioVenture Partners Investment Advisor LLC | 5.4% | 1,926,943 | 13% | $32,989,264 | |
| ANDERA PARTNERS | 5.3% | 1,897,362 | 0% | 18% | $32,482,837 |
| Nan Fung Group Holdings Ltd | 4% | 1,441,032 | 22% | $24,670,468 | |
| JPMORGAN CHASE & CO | 3.6% | 1,308,901 | 0% | $22,408,385 | |
| RTW INVESTMENTS, LP | 3.6% | 1,283,671 | 0.22% | $21,976,448 | |
| SymBiosis Capital Partners, LLC | 3.6% | 1,280,778 | 0% | 23% | $21,926,919 |
| MARSHALL WACE, LLP | 2.7% | 988,200 | 0.02% | $16,917,986 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 2.7% | 961,525 | 0.26% | $16,461,308 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.2% | 782,121 | 0% | $13,391,000 | |
| SECTORAL ASSET MANAGEMENT INC | 1.6% | 589,005 | 8.1% | $10,083,766 | |
| Verition Fund Management LLC | 1.6% | 565,214 | 0.05% | $9,676,464 | |
| Aberdeen Group plc | 1.5% | 525,376 | 0.01% | $8,994,437 | |
| Velan Capital Investment Management LP | 1.4% | 506,754 | 5% | $8,675,628 | |
| VANGUARD GROUP INC | 1.4% | 502,574 | 0% | $8,604,067 | |
| Octagon Capital Advisors LP | 1.4% | 500,000 | 1.1% | $8,560,000 | |
| AMERICAN CENTURY COMPANIES INC | 1.2% | 417,455 | 0% | $7,146,850 | |
| GREAT POINT PARTNERS LLC | 0.9% | 325,000 | 1.8% | $5,564,000 | |
| FEDERATED HERMES, INC. | 0.9% | 325,000 | 0.01% | $5,564,000 | |
| NEXTBio Capital Management LP | 0.63% | 228,286 | 0% | 2.3% | $3,908,256 |
| Defilade Capital Management, L.P. | 0.6% | 215,418 | 0% | 0.5% | $3,687,956 |
| Kynam Capital Management, LP | 0.52% | 185,482 | 0.21% | $3,175,452 | |
| ADAR1 Capital Management, LLC | 0.51% | 184,062 | 0.24% | $3,151,141 | |
| Monashee Investment Management LLC | 0.51% | 183,239 | 1.8% | $3,137,052 |